Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA +0.24%51 PB Ratio is 2.94 as of Jul. 27, 2026, which is 10% above its 10-year median of 2.68. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 51/100 and a GF Value™ of ₹176.22 (Fairly Valued). The stock has 5 warning signs investors should review. Among 924 Drug Manufacturers companies, Piramal Pharma ranks worse than 67.53% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-27), Piramal Pharma's share price is ₹181.27. Piramal Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was ₹61.62. Hence, Piramal Pharma's PB Ratio of today is 2.94.
The historical rank and industry rank for Piramal Pharma's PB Ratio or its related term are showing as below:
NSE:PPLPHARMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.2 Med: 2.68 Max: 4.7
Current: 2.94
During the past 6 years, Piramal Pharma's highest PB Ratio was 4.70. The lowest was 1.20. And the median was 2.68.
NSE:PPLPHARMA's PB Ratio is ranked worse than 67.53% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs NSE:PPLPHARMA: 2.94
During the past 12 months, Piramal Pharma's average Book Value Per Share Growth Rate was 0.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Piramal Pharma was 21.20% per year. The lowest was 3.50% per year. And the median was 3.80% per year.
Back to Basics: PB Ratio
Piramal Pharma (NSE:PPLPHARMA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Piramal Pharma PB Ratio Related Terms
Piramal Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Piramal Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Piramal Pharma (NSE:PPLPHARMA) has a PB Ratio of 2.94 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Piramal Pharma and its competitors. This is 10% above median its historical median of 2.68. Over the past decade, Piramal Pharma's PB Ratio has ranged from 1.20 to 4.70. According to the industry distribution chart, Piramal Pharma ranks #624 out of 924 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Piramal Pharma's PB Ratio too high?
Piramal Pharma's current PB Ratio of 2.94 is 10% above median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 4.70. The Drug Manufacturers industry median PB Ratio is 1.90. Piramal Pharma's value of 2.94 is 54.7% above this industry median. Based on the distribution chart, Piramal Pharma ranks #624 out of 924 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #624 out of 924 companies for PB Ratio. This places Piramal Pharma in the lower half of its industry. The industry median PB Ratio is 1.90. Piramal Pharma's value of 2.94 is 54.7% above this benchmark. Historically, Piramal Pharma's own PB Ratio has ranged from 1.20 to 4.70 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 1.90, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current PB Ratio of 2.94 is 54.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current PB Ratio is 2.94, which is 10% above median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹176.22, compared to a current price of ₹181.27 — trading 2.9% above its estimated fair value. The current PB Ratio is 2.94, which is 10% above median its 10-year median of 2.68 and 54.7% above the Drug Manufacturers industry median of 1.90. Piramal Pharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current PB Ratio is 2.94 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹181.27 is trading 2.9% above its estimated GF Value™ of ₹176.22.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
PB Ratio: 2.94 (10% above median its 10-year median of 2.68)
GF Value™: ₹176.22 vs. price of ₹181.27 (2.9% above fair value)
Industry Position: 54.7% above the Drug Manufacturers median (#624 of 924)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score
Get the complete analysis for NSE:PPLPHARMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
